Quanquan Ding

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial”.

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Cancer Cell(2024)10.1016/j.ccell.2024.10.007

N/A

1.3DataRank · unranked

59 citations

Robert M. Morrison, Amiran Dzutsev, Arivarasan Karunamurthy, Joë-Marc Chauvin, F. Amatore +48 more

Targeting novel inhibitory receptors in cancer immunotherapy

Seminars in Immunology(2020)10.1016/j.smim.2020.101436

N/A

0DataRank · unranked

15 citations

Joë-Marc Chauvin, Hassane M. Zarour, Quanquan Ding

A Requirement of Protein Geranylgeranylation for Chemokine Receptor Signaling and Th17 Cell Function in an Animal Model of Multiple Sclerosis

Frontiers in Immunology(2021)10.3389/fimmu.2021.641188

N/A

0DataRank · unranked

6 citations

Jia Geng, Eunchong Park, Quanquan Ding, John Zhou, Ciana Walcott +5 more

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

Nature Medicine(2022)10.1038/s41591-022-01698-2

N/A

0DataRank · unranked

445 citations

Diwakar Davar, Richard R. Rodrigues, Jonathan H. Badger, Jennifer R. Fang, Alicia M. Cole +26 more

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0575

N/A

0DataRank · unranked

146 citations

Mignane Ka, Ornella Pagliano, Carmine Menna, Quanquan Ding, Richelle DeBlasio +11 more

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0605

N/A

0DataRank · unranked

4 citations

Joë-Marc Chauvin, Robert Morrison, Yulong Bai, Jie Sun, Hong Wang +22 more

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Research Square(2022)10.21203/rs.3.rs-2235839/v1

N/A

0DataRank · unranked

1 citations

Arivarasan Karunamurthy, Joë-Marc Chauvin, Robert M. Morrison, Yulong Bai, Jie Sun +40 more

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Journal of Clinical Investigation(2022)10.1172/jci152864

N/A

0DataRank · unranked

69 citations

Robert M. Morrison, Joë-Marc Chauvin, Hridesh Banerjee, Diwakar Davar, Quanquan Ding +28 more